Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Holding PTGX?
Track your performance easily
PTGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.01 - $48.89
Previous Close$41.11
Volume1.09M
Average Volume (3M)603.23K
Market Cap
$2.45B
Enterprise Value$1.99B
Total Cash (Recent Filing)$468.72M
Total Debt (Recent Filing)$10.90M
Price to Earnings (P/E)15.4
Beta0.21
Next Earnings
Mar 18, 2025EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.67
Shares Outstanding59,598,018
10 Day Avg. Volume702,797
30 Day Avg. Volume603,229
Standard Deviation0.29
R-Squared0.15
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.60
Price to Sales (P/S)7.55
Price to Cash Flow (P/CF)-22.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.15
Enterprise Value/Gross Profit33.20
Enterprise Value/Ebitda11.77
Forecast
1Y Price Target
$55.83Price Target Upside35.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Protagonist Therapeutics News
PremiumCompany Announcements
Protagonist Therapeutics Reports Strong Financial Turnaround
PremiumCompany Announcements
Protagonist Therapeutics Board and Audit Committee ChangesBulls Say, Bears Say
Bulls Say
Clinical Efficacy And ProspectsJNJ-2113's Phase 2b psoriasis data show efficacy better than any available oral therapy and equivalent to injectables, signaling a high probability of success for the four Phase 3 studies.
Market OpportunityJNJ-2113, with its potential to serve a large unmet need for a safe oral treatment, is well-positioned to capture a share of the $35 billion psoriasis market, which is expected to be more receptive to new oral options.
Pipeline And CollaborationsProtagonist's peptide technology platform has produced two Phase 3-stage candidates targeting multi-billion dollar market opportunities, supported by a strong partnership in developing an oral IL-23 inhibitor for psoriasis and an iron modulator for polycythemia vera.
Bears Say
Clinical TrialsRisks include unexpected safety concerns in ongoing clinical trials and potential increased regulatory, competitive, and pricing risks.
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Partnership RisksRisks include partner JNJ potentially not pursuing JNJ-2113, and increased regulatory, competitive, and pricing risks.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $16.01 and its highest was $48.89 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2025 which is in 117 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.578 by $0.038.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -$0.09.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 59,598,020 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.578. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 263M.
---
Protagonist Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.83 (35.81% Upside)
$55.83 (35.81% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $631.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.36%
12-Months-Change
Fundamentals
Return on Equity
40.97%
Trailing 12-Months
Asset Growth
82.98%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$55.83
▲(35.81% Upside)
Technical Analysis
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
18/18 ratings generated profit
1 Year Average Return
+81.11%
reiterated a buy rating 4 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +81.11% per trade.
---